1. Home
  2. HOWL vs HIND Comparison

HOWL vs HIND Comparison

Compare HOWL & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Werewolf Therapeutics Inc.

HOWL

Werewolf Therapeutics Inc.

HOLD

Current Price

$0.32

Market Cap

18.9M

Sector

Health Care

ML Signal

HOLD

Logo Vyome Holdings Inc.

HIND

Vyome Holdings Inc.

N/A

Current Price

$2.16

Market Cap

15.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
HOWL
HIND
Founded
2017
2017
Country
United States
United States
Employees
N/A
18
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.9M
15.2M
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
HOWL
HIND
Price
$0.32
$2.16
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
1
Target Price
$5.00
$15.00
AVG Volume (30 Days)
647.6K
19.4K
Earning Date
05-05-2026
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
18.40
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.33
$1.75
52 Week High
$2.23
$12.87

Technical Indicators

Market Signals
Indicator
HOWL
HIND
Relative Strength Index (RSI) 30.92 48.69
Support Level N/A $1.99
Resistance Level $0.74 $2.40
Average True Range (ATR) 0.04 0.14
MACD 0.01 -0.01
Stochastic Oscillator 8.15 22.22

Price Performance

Historical Comparison
HOWL
HIND

About HOWL Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.

About HIND Vyome Holdings Inc.

Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.

Share on Social Networks: